Akebia Therapeutics, Inc. (AKBA)

$0.389

+0.04 (+10.17%)
Rating:
Recommendation:
Buy
Symbol AKBA
Price $0.389
Beta 1.549
Volume Avg. 13.41M
Market Cap 71.394M
Shares () -
52 Week Range 0.3-3.709
1y Target Est -
DCF Unlevered AKBA DCF ->
DCF Levered AKBA LDCF ->
ROE -266.13% Strong Sell
ROA -51.49% Strong Sell
Operating Margin -
Debt / Equity 1949.92% Strong Buy
P/E -
P/B 2.68 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest AKBA news


Mr. John Butler
Healthcare
Biotechnology
NASDAQ Global Market

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.